BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
Public ClinicalTrials.gov record NCT02054481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.
Study identification
- NCT ID
- NCT02054481
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 166 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2014 (Type not available)
- Primary completion
- Nov 2014 (Actual)
- Completion
- Jul 2015 (Actual)
- Last update posted
- Sep 19, 2016
2014 – 2015
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1311.2.10010 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1311.2.10013 Boehringer Ingelheim Investigational Site | Port Orange | Florida | — | — |
| 1311.2.10003 Boehringer Ingelheim Investigational Site | Arlington Hts | Illinois | — | — |
| 1311.2.10002 Boehringer Ingelheim Investigational Site | Bay City | Michigan | — | — |
| 1311.2.10004 Boehringer Ingelheim Investigational Site | Fridley | Minnesota | — | — |
| 1311.2.10001 Boehringer Ingelheim Investigational Site | East Windsor | New Jersey | — | — |
| 1311.2.10009 Boehringer Ingelheim Investigational Site | Verona | New Jersey | — | — |
| 1311.2.10007 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1311.2.10005 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1311.2.10006 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1311.2.10011 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1311.2.10012 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02054481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2016 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02054481 live on ClinicalTrials.gov.